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[—William Gibson]1. So sue me
Myriad Genetics, founded in 1991 as a spin-off from the cancer ge-
netics epidemiology unit at the University of Utah and initially funded
in part by publicmoney, went on to build amulti-billion-dollar business
bydiscovering andpatenting two genes that,whenmutated, predispose
to hereditary breast and ovarian cancer (HBOC) (Williams-Jones, 2002;
Allison, 2014). While Myriad's reputation as a competent test provider
was generally exemplary and there was no apparent price premium at-
tributable to the patents, the company's monopoly on the two genes
kept patients from obtaining second opinions or conﬁrmatory testing.
Moreover, researchers were prevented from returning results on the
two genes to research participants (Carbone et al., 2010; Cook-Deegan
et al., 2010). In 2009 the American Civil Liberties Union sponsored
litigation against Myriad on behalf of twenty plaintiffs (including
HBOC patients), seeking to overturn Myriad's US service monopoly on
genetic testing for HBOC. In 2013 the United States Supreme Court
ruled that genomic DNA was a product of nature and therefore not
patentable (Association for Molecular Pathology et al., 2013), while
engineeredDNAmoleculeswere eligible to patent. Almost immediately,
a spate of other genetic testing ﬁrms announced that they would begin
testing for the two genes, BRCA1 and BRCA2, that were once the exclu-
sive province of Myriad (Karow, 2013).
But, as Conley et al. describe in their reviewof theHBOC genetic test-
ing landscape post-Myriad, whatever the legal precedent the Supreme
Court established, in the immediate aftermath of the decision the
HBOC marketplace only became messier and more confusing (Conley⁎ Corresponding author.
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post-SCOTUS, Myriad ﬁled suit against most of its new would-be com-
petitors, some of whom countersued while Gene by Gene acquiesced
and settled out of court in February 2014 (Allison, 2014; Conley et al.,
2014; Sherkow and Scott, 2014). Others have tried to be proactive be-
fore launching their own HBOC tests, seeking declaratory court judg-
ments that would allow them to enter the market without fear of
litigation (Conley et al., 2014). In all, thus far eight ﬁrms have been
sued byMyriad, one settled, and several have countersued; the ongoing
cases have been consolidated in the US Federal District Court for Utah,
Judge Robert Shelby presiding. In all likelihood, the legal wrangling
will outlive the ﬁrst and broadest of Myriad's surviving patent claims
on BRCA1 and BRCA2, which begin to expire in 2015.
Litigation and uncertainty ensure a contentious and turbulent HBOC
genetic testing market in the near term. But while Myriad's patent es-
tate may be vulnerable, the company retains a two-decade head start
on its competition and a war chest in excess of $250 million (Gleason
et al., 2014b). That is why, at least in part, it seems to us that it is not
litigation but rather Myriad's other major post-SCOTUS commercial
strategy – to keep its data as a trade secret in the name of “accuracy”
(Tucker, 2014) – that is more important and could set a worrisome pre-
cedent for the future of precisionmedicine, which relies on transparen-
cy as to how the work was done and broad access to data in order to
replicate initial ﬁndings and draw robust conclusions about the use of
genomics in clinical care (Angrist and Jamal, 2014).
2. The sagacity of opacity?
Myriad's nearly two decades of control over the BRCA1 and BRCA2
genes allowed it to amass a large proprietary database of variants in
these genes (Cook-Deegan et al., 2013). To its credit, company scientists
have classiﬁed more than 25,000 mutations in cancer-related genes
with respect to their pathogenicity (Gleason et al., 2014b). According
to Myriad, its rate of variants of unknown signiﬁcance (VUS), that is,
BRCA variants whose pathogenicity (or lack thereof) cannot be deter-
mined with high certainty, was down to 2% in 2013–2014 versus 13%the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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indeed.
WhatMyriad has not done for ten years, however, is share those var-
iant classiﬁcations with the broader scientiﬁc community (Tucker,
2014; Cook-Deegan et al., 2013), which means its VUS rate is unveriﬁ-
able by anyone outside of the company. Why has Myriad declined to
share its data? In recent months it has taken the opportunity to slam
public databases time and again for their presumptive inaccuracy, lack
of oversight/curation and the liability risks attached to using informa-
tion contained within them to make clinical decisions (Gleason et al.,
2014a; Bowles, 2014; Gleason et al., 2014b; Ray, 2014b). Public data-
bases, according to Myriad's Chief Medical Ofﬁcer, are not “sufﬁciently
clinic-ready” and their VUS rate is unacceptably high (Tucker, 2014).
Fine. Let's concede that: 1) public databases harboring cancer-
related variants like ClinVar and the Breast Cancer Information Core
(BIC) along with the hundreds of locus-speciﬁc databases and handful
of other genome-wide variant databases have inaccuracies in them —
all databases do, of course, because as the science improves, variants
will inevitably be re-classiﬁed; and 2) there is arguably a greater incen-
tive for commercial laboratories returning results to patients and sub-
ject to liability concerns to ensure that variant classiﬁcations are
accurate for clinical purposes.
But, aswe and others have argued elsewhere, the onlyway these da-
tabases will improve, and the promise of personalized medicine will be
realized, is through broad data-sharing, not construction of new silos
and fortiﬁcation of existing ones (Field et al., 2009; Angrist and Jamal,
2014; Quackenbush, 2014). Data quality – and by extension, patient
care and liability mitigation – improves when the data have more eyes
on them, not fewer. Myriad's withholding data impoverishes the public
databases, while sharing data does not hinder Myriad's use of either its
own data or public data. If other labs do as Myriad has, we will have –
forgive us – a myriad of private, competitive databases to the detriment
of all. Recently, in light of their discovery that family history of breast
and ovarian cancer is an inadequate predictor of familial risk on its
own (Gabai-Kapara et al., 2014), HBOC pioneer Mary-Claire King and
colleagues called for universal screening of BRCA1/2 in women after
age 30 (King, et al., 2014). Whatever the merits and ﬁnancial/logistical
challenges of such an undertaking (and we should not underestimate
the latter), in the near term how feasible would it be to expand HBOC
genetic testing bymanyorders ofmagnitudewhilemost of the allelic in-
terpretation data remain inaccessible to anyone outside of Myriad?
3. Legerdemain and the public domain
Myriad's position is that if public databases are not “clinic-ready”
then the company will simply take its ball and go home. And so it has.
But of course this is a non sequitur.
There is nothing preventing Myriad from publishing its own muta-
tion data wherever it wants and curated however it wants to whatever
exacting standards it wishes. Commercial laboratories certiﬁed in accor-
dance with the Clinical Laboratory Improvement Amendments of 1988
(CLIA) deposit their genetic disease-related variants in public databases
all the time and the genomics community has developed professional
standards and guidelines for assessing those variants, whatever their
source (Duzkale et al., 2013; Rehm et al., 2013; MacArthur et al.,
2014). Are CLIA-certiﬁed clinical variant data rendered suspect just be-
cause they sit alongside variants generated by research laboratories?
Myriad is not obligated to share its data (at least not yet); it is free
to treat cancer-causing variants the way the Coca-Cola Company
does its vaunted soft-drink formula (Kolata, 2013; Conley et al., 2014).
But the company should at least do us the service of giving it to us
straight. The “public databases aren't good enough for our data” argu-
ment is an eye-roller. The simplest way to improve public databases is
to populate them with data and to play an active role in ensuring
that the standards for interpretation are rigorous.Myriadwould assume
no more liability for depositing data than the dozens of otherlaboratories that already do so for countless genetic diseases. Recently,
Myriad's Chief Medical Ofﬁcer told a reporter that the company would
consider sharing its data if it could do so without competing laboratories
exploiting the information for their own HBOC testing efforts (Tucker,
2014). This complaint strikes us as a far cry from concerns over inade-
quate databases.
Earlier this year, on a quarterly conference call with investment an-
alysts (Gleason et al., 2014a), Myriad CEO Peter Meldrum discussed
olaparib, a chemotherapeutic agent currently in Phase III clinical trials
that is accompanied by BRCA testing for patient selection because data
suggest that the drug is more effective in HBOC and prostate cancer pa-
tients with germline BRCA1 or BRCA2mutations (Lee et al., 2014). Be-
cause Myriad's BRCAmutation database is deeper and more extensive
than the public's (due in part toMyriad ceasing its variant contributions
to public databases a decade ago), olaparib testingwill allow the compa-
ny to expand its franchise further into large-scale mutation detection in
cancer. Meldrum:
… our competitors' reliance on public databases with high VUS and
error rates will further restrict patient access to this life-saving
medicine.
[Gleason et al. (2014a)]
Meldrum's clumsy assertion that ill people will suffer because other
HBOC testing companies do not have access to Myriad's data is indeed a
cruel reality, a claim of strategic business advantage rooted in a morally
suspect choice. And let's be clear: it is a business choice, not a legal obli-
gation. And yes, withholding data relevant to interpretation of genetic
test results everywhere in the world outside of a single laboratory as a
business strategy is a moral issue. Nothing personal, cancer patients…
it's just business.
For its part, Myriad is contributing variants to the Prospective Regis-
try of Multiplex Testing (PROMPT), an academic–commercial partner-
ship designed to create a registry of patients who have undergone
multiplex genetic testing, curate their data, and characterize their ge-
netic variants (Myriad, 2014). So, will this registry include BRCA1/2 var-
iants? Not many. “The genes of focus in this study are the less-studied
genes that are now appearing on pan-cancer panels,” according to a
Myriad spokesman (Ray, 2014a). The academic principal investigator
of the study conﬁrmed to one of us (MA) that PROMPT will be “concen-
trating on non-BRCA predispositions” (M. Robson, personal communi-
cation, 18 August 2014).
PROMPT is a laudable effort to improve interpretation of many can-
cer variants, andMyriad's participation is welcome. It can also, perhaps,
set a precedent for future efforts to pool data. But it does not obviate the
abiding policy issue confronting the system: as things stand, incentives
make data-hoarding a commercial advantage. Payers should beware:
the precedents beginning to take hold now will set the pace for future
costs of genetic testing. Without the principles of data-sharing and
transparent analysis as prior conditions for coverage, reimbursement,
and accreditation of genetic testing, proprietary data strategies may
well proliferate, and costs will rise accordingly. If payers, accreditors
and governing bodies choose to remain toothless, precision medicine
will be less effective and more expensive. It really is that simple.
4. Reverse engineer agonistes
A couple of years ago, a consortiumof advocates, academics and clin-
ical diagnostic laboratories led by Robert Nussbaum at the University of
California, San Francisco, launched Free the Data (http://www.free-the-
data.org/) and Sharing Clinical Reports (http://www.iccg.org/about-
the-iccg/collaborations/sharing-clinical-reports-project/). Meanwhile,
the Evidence-based Network for Interpretation of Germline Mutant Al-
leles (ENIGMA) consortium received anNIH stimulus grant to systemat-
ically characterize BRCA mutations of unknown signiﬁcance using a
multitude of biological, computational, and other methods (Spurdle
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BRCA co-discoverers) who chose to work instead in the public domain.
And investigators with the Global Alliance for Genomics and Health, a
consortium of institutions working in healthcare, research, disease
advocacy and bioinformatics, are pooling data from all over the world
on variants from current sequencing efforts in HBOC (Hayden, 2014)
(http://genomicsandhealth.org/our-work/working-groups/clinical-
working-group). These efforts are part of a noncommercial grassroots
movement to collect BRCA1/2 variants from clinicians and patients,
characterize and interpret them, and deposit them in ClinVar and
other open-access databases (Lambertson and Terry, 2014); in other
words, they are an effort to re-engineer Myriad's database.
While we see these activities as extremely noble undertakings, it is
inﬁnitely more important that HBOC survivors, previvors and advocacy
groups see them that way and are willing to contribute their data
(Tucker, 2014; Lambertson and Terry, 2014). But will they work? In
2013 Nussbaum estimated that he had reconstructed 1.5% of Myriad's
BRCA1/2 database (Kolata, 2013). Based on a series of informal conver-
sations, Conley et al. (2014) guessed that, as of mid-2014, the public da-
tabases had collectively amassed some 20–25% of Myriad's data.
Meanwhile, as of late August 2014, just seven of the 78 labs offering
BRCA testing (as listed in both genetests.org and the Genetic Testing
Registry [http://www.ncbi.nlm.nih.gov/gtr/]) had committed to depos-
iting their BRCA1/2 data into ClinVar (http://www.free-the-data.org/;
last accessed on 20 August 2014).
Why such slowuptake? It is difﬁcult to know for certain, but a couple
of factors are likely at work. One is the time and effort involved. Clinical
laboratories are busy places and pulling clinical reports for two speciﬁc
genes among thousands can be a headache. It is noteworthy that
Nussbaum's yield increased substantially when he started offering
micropayments to labs for sharing BRCA variants (Kolata, 2013).
The other factor, we suspect, is politics. Myriad collaborates with
dozens of clinicians and research scientists. While the company might
no longer be able to wield genomic DNA patents as a cudgel, it remains
the alpha dog in HBOC testing; its own estimate as of August 2014 was
that it retained 92% of the HBOC genetic testing market (Gleason et al.,
2014b). A number of oncologists and cancer geneticists we have spoken
with informally, while sympathetic with the goals of Free the Data, are
nevertheless loath to antagonize Myriad. Moreover, they obviously
want the best for their patients, and many are content to send samples
to Myriad for analysis.
One of the ironies is that the Supreme Court decision means the
Myriad service monopoly that enabled the proprietary database to
form rested on patent claims granted in error by the US Patent and
Trademark Ofﬁce. Myriad gained from those mistakes until June 2013,
and now the database built on those mistakes further beneﬁts Myriad
due to inaction among accreditors and payers.
5. Redistributing the future
What to do, then, tomake the BRCA1/2 knowledge-base more wide-
ly available? Time will likely prove salutary: expirations on the earliest
and broadest patents, which begin next year (Conley et al., 2014), may
make would-be BRCA variant depositors feel less inhibited about shar-
ing their test reports. And if, as Nussbaum's experience suggests, re-
trieval of such reports would beneﬁt from some modest subsidy, one
could imagine the Free the Data community and a coalition of willing
partners soliciting donations from its supporters to expedite such
retrievals.
Another promising approach appeals to patients directly to secure
their BRCA results. Forwhat it'sworth, this has never beenmore feasible
than it is now: As of February 2014, the US Department of Health and
Human Services amended CLIA to allow patients access to their
completed test reports at their or their representatives' request. While
patients can continue to get access to their test results from their doc-
tors, the 2014 rule provides for patient access directly from the clinicallaboratory. The rule is not without hurdles: patients must put their re-
quest inwriting andmaybe charged for the costs of photocopying,mail-
ing and/or electronic media such as ﬂash drives. But assuming these
requirements are met, in most cases the patient's request must be hon-
ored within 30 days (Medicare et al., 2014).
Ultimately, Myriadwill ﬁnd that hoarding is not in its own interests.
The recent discovery that female carriers of loss-of-function mutations
in the gene PALB2 have a risk of developing breast cancer by age 70 of
35% (and in some cases as high as 58%) is another potent reminder
that BRCA1/2mutations are a necessary but insufﬁcient component of
the HBOC story (Antoniou et al., 2014). With costs now $1000 for gen-
eratingwhole-genome sequence raw data (Herper, 2014), the technical
and ﬁnancial barriers to comprehensive genetic assessments of HBOC
risk are falling away.
Myriad's own MyRisk test of 25 cancer genes is scheduled to sup-
plant its BRCA-based BRACAnalysis® by mid-2015 (Gleason et al.,
2014b), and every cancer clinic is experimenting with cancer panels,
if not ordering them regularly. Illumina has been in the genomic se-
quencing business for longer than Myriad, and it has a database with
more than twice as many variants as Myriad's across nearly 2000
genes (E. Ramos, personal communication, 22 August 2014). There
will be no service monopoly on multiplex cancer panel testing, exome
sequencing, or whole-genome analysis; thus, no one ﬁrm can create a
database as dominant for the human genome writ large as Myriad's is
for BRCA1/2 variants.
So long as incentives remain as they are, the value of Myriad's data-
basewill dissipate and eventually it will make no sense for the company
to expend resources onmaintaining its own database of marginal value,
but that depends on the rest of the network developing databases and
analytical tools equal to the task. In the meantime, it is understandable
but unfortunate for the system as a whole that Myriad has chosen to
build a business model around closely held clinical data.
Myriad has long been willing to wear the black hat (Baldwin and
Cook-Deegan, 2013). The quality and speed of its BRCA testing services
and resulting support from patients and clinicians have made that hat
worth wearing. The company's approach may remain ﬁnancially viable
for a while. But in a whole-genome world where disease risk is mediat-
ed by a panoply of genes and patients are increasingly mobilized to de-
mand their data, sooner or later private databases will become an
maladaptive strategy.
One black mark that is rarely noted is the impact of Myriad's strate-
gic behavior outside the hotly contested and highly lucrative US BRCA
testing market. The effects of the battle for US genetic testing affect
the whole world. Myriad reported $10 million a week in revenues for
BRCA testing in 2013–14: $517million out of total revenues of $778mil-
lion (Anonymous, 2014). That revenue stream, which has produced
$2.8 billion in revenues since 2004, drives Myriad's litigation and data-
base secrecy strategies. Women throughout the world are casualties of
the dysfunctional US market, which created incentives for data-
hoarding. Thus far public sources have failed to build the infrastructure
to interpret genomic variants that would obviate such business strate-
gies, so that while women tested in Malawi and Manhattan face the
same choices, the ones in Manhattan are much more likely to be
able to overcome barriers to follow-up given their access to a higher
baseline of both primary and specialty care thanwomen in the develop-
ing world. Unlike the medical literature that is curated for world
use and available anywhere – to the immense beneﬁt of patients
everywhere – genomic variant data are cloaked in secrecy due to the
way some US stakeholders are playing the genetic testing game. If you
want your BRCAmutation to be interpretedwith the best data available,
you have to get both the test and the interpretation performed by a US
company in Salt Lake City, whether you live in Moscow, Idaho, or
Moscow, Russia. The September 2014 decision by the Federal Court of
Australia to uphold Myriad's isolated genomic DNA patents (despite
an historical lack of enforcement) suggests that the notion that genetic
testing requires monopolies even in mature markets is not quite dead
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Until that changes testing and interpretation can be forcibly bundled
worldwide because of a two-decade US patent monopoly that never
should have existed; the market for cystic ﬁbrosis genetic testing, for
example, seems to have developed just ﬁne in the absence of a patent
monopoly (Minear et al., 2013).
Even without erosion of its patent estate, it is simply not plausible
that Myriad will become the sole permanent home to data on most
genes, or even most cancer genes, in the human genome. Its two-gene
US monopoly will not generalize. In the end, data must be pooled to
be useful, and open, public databases must house clinically relevant in-
formation. How fast we build the tools needed for analysis of genomic
variants depends not only on how many laboratories adopt data-
hoarding strategies and thereby slow the process, but also on how
well and how fast the public databases and norms of science and clinical
practice build the requisite infrastructure and sharing practices. The sys-
tem will hum when proprietary data strategies are fruitless because
public resources are robust. It's a huge undertaking… so we'd better
get started.
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